Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Second Quarter 2013 Financial Results

      - Company confirms full year sales and profit guidance, expects strong second half -

      - Company to host conference call at 8:30 a.m. ET on August 1, 2013 -


      News provided by

      Cambrex Corporation

      Aug 01, 2013, 07:00 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Aug. 1, 2013 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the second quarter ended June 30, 2013.

      Highlights

      • Second quarter sales decreased to $61.6 million from $77.1 million in the second quarter of 2012. 
      • Second quarter EBITDA decreased to $11.4 million compared to $19.2 million in the second quarter of 2012 (see table at the end of this release). 
      • Debt, net of cash was $67.5 million at the end of the second quarter, an increase of $26.3 million during the quarter. 
      • 2013 full year sales and EBITDA guidance confirmed (see Financial Expectations section).

      "The first half of 2013 compared unfavorably to the same period last year given the exceptional results in the first half of last year.  We expect a considerably stronger second half of 2013, and remain on track to achieve our full year guidance for both sales and EBITDA," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.  "We are very pleased with the performance of our new large scale GMP manufacturing facility in Charles City, Iowa and the progress we are making on producing commercial launch quantities of our customer's exciting new therapeutic.  We recently signed an agreement for a new late stage clinical project and received verbal approval for a second from another customer, indicating continued strong custom development demand."

      Second Quarter 2013 Operating Results – Continuing Operations

      Sales of $61.6 million were 20.1% lower compared to the same period last year, including the favorable impact of foreign exchange of 1.4%.  This decrease was primarily due to lower sales of controlled substances and generic APIs.

      Gross margins decreased to 31.2% from 36.9% compared to the same period last year.  This decrease was primarily due to unfavorable product mix.  Foreign exchange negatively impacted gross margins 0.5% in the second quarter of 2013. 

      Selling, general and administrative expenses were $10.6 million compared to $12.0 million in the same period last year.  The decrease was mainly due to lower personnel expenses.

      Research and development expenses were $2.8 million compared to $2.6 million in the same period last year. 

      Operating profit decreased to $5.9 million from $13.9 million in the same period last year. The decrease in operating profit was primarily the result of lower gross profit partially offset by lower SG&A expenses.  EBITDA was $11.4 million compared to $19.2 million in the same period last year. 

      Net interest expense was $0.5 million compared to $0.7 million in the same period last year.  This decrease was primarily a result of higher capitalized interest as a result of multiple large capital projects as well as lower average debt.

      Equity in losses of partially-owned affiliates was $0.7 million compared to $0.4 million in the same period last year. The Company's portion of Zenara's loss for the second quarters of 2013 and 2012 was $0.5 million and $0.4 million, respectively.  These amounts include amortization expense of $0.2 million for the second quarters of 2013 and 2012. 

      The provision for income taxes in the second quarter of 2013 totaled $1.5 million and resulted in an effective tax rate of 32.8%. 

      Income from continuing operations for the second quarter of 2013 was $3.1 million or $0.10 per share compared to $9.9 million or $0.33 per share in the same period last year. 

      Capital expenditures and depreciation for the second quarter of 2013 were $13.1 million and $5.5 million, respectively, compared to $4.3 million and $5.3 million in the same period last year, respectively.  The increase in capital expenditures in the quarter was primarily driven by expansion of the Company's large-scale manufacturing capacity to support expected growth in demand for products requiring these assets.

      Financial Expectations – Continuing Operations

      The Company continues to expect that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% over 2012, and that full year 2013 adjusted EBITDA will be between $62 and $68 million, an increase of 8% to 18% over 2012.  While the Company does not expect to pay cash taxes in the U.S. for the next few years, the Company is recording tax expense on U.S. income for the first time in several years beginning in 2013.  The Company estimates that its 2013 consolidated effective tax rate will be between 32% and 36%, which reduces the previous estimate of 38% at the high end of the range.  The tax rate will be sensitive to the geographic mix of income and quarterly effective tax rates may be volatile. 

      Capital expenditures are expected to be approximately $36 to $40 million and depreciation is expected to be $22 to $24 million in 2013.

      These financial expectations are for continuing operations and exclude the impact of any potential M&A, restructuring activities and outcomes of tax disputes, and do not reflect the Company's stake in Zenara, which is accounted for using the equity method.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's second quarter 2013 Form 10-Q is filed with the SEC.

      Conference Call and Webcast

      A conference call to discuss the Company's second quarter 2013 results will begin at 8:30 a.m. Eastern Time on Thursday, August 1, 2013 and last approximately 45 minutes.  Those wishing to participate should call 1-888-523-1225 for domestic and +719-325-2362 for international.  Please use the pass code 9218097 and call approximately 10 minutes prior to start time.  A webcast will be available on the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Thursday, August 8, 2013 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 9218097 to access the replay. 

      About Cambrex

      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

      Forward Looking Statements

      This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," including the Company's expectation that the second half of 2013 will be considerably better than the first half of the year, including that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% versus 2012, that full year 2013 adjusted EBITDA will be between $62 and $68 million, that capital expenditures will be approximately $36 to $40 million and that depreciation will be $22 to $24 million in 2013.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2012, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2012, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products and the Company's ability to move forward on the new verbally-approved late stage project on the anticipated schedule and terms, as well as risks relating to a Phase 3 supply agreement signed during 2012 including that the Company will expend significant resources to expand its manufacturing facilities without any assurance that the new agreement will generate any revenue beyond revenue that would be earned under termination provisions within the agreement, that the customer's product candidate will be successful in Phase 3 trials or obtain the necessary regulatory approvals to commercialize the product candidate, that the customer's Phase 3 program will not be terminated early, that anticipated quantities will not be meaningfully reduced, that the planned Phase 3 and pre-launch activities will proceed on the timeline anticipated, if at all, and that the progress we are making on producing commercial launch quantities of our customer's new therapeutic will continue on the anticipated timeline, which will require, among other variables, that our new large scale GMP manufacturing facility in Charles City, Iowa continues to ramp up and produce as anticipated.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

      Use of Non-GAAP Financial Measures

      EBITDA is a non-GAAP financial measure, which the Company defines as operating profit plus depreciation and amortization expense.  Other companies may have a different definition of EBITDA and, therefore, EBITDA may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA as one of several metrics to assess and analyze its operational results and trends.  Cambrex also believes it is useful to investors because it is a common operating performance metric as well as a metric routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation from U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended June 30, 2013 and 2012

      (in thousands, except per-share data)













      2013



      2012





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      61,628




      $

      77,142



           Commissions, Allowances and Rebates


      65





      781



      Net Sales


      61,563





      76,361













           Other


      1,240





      772













      Net Revenues


      62,803





      77,133













           Cost of Goods Sold


      43,552


      70.7%



      48,688


      63.1%











      Gross Profit


      19,251


      31.2%



      28,445


      36.9%











      Operating Expenses










           Selling, General and Administrative Expenses


      10,622


      17.2%



      11,959


      15.5%

           Research and Development Expenses


      2,765


      4.5%



      2,592


      3.4%

      Total Operating Expenses


      13,387


      21.7%



      14,551


      18.9%











      Operating Profit


      5,864


      9.5%



      13,894


      18.0%











      Other Expenses:










           Interest Expense, net


      488





      678



           Other Expenses, net


      38





      16



           Equity in Losses of Partially-Owned Affiliates


      668





      383













      Income Before Income Taxes


      4,670


      7.6%



      12,817


      16.6%











           Provision for Income Taxes


      1,534





      2,889













      Income from Continuing Operations

      $

      3,136


      5.1%


      $

      9,928


      12.9%











      Loss from Discontinued Operations, Net of Tax


      (862)





      -













      Net Income

      $

      2,274


      3.7%


      $

      9,928


      12.9%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.10




      $

      0.34



         Loss from Discontinued Operations, Net of Tax

      $

      (0.03)




      $

      -



         Net Income

      $

      0.07




      $

      0.34













      Diluted Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.10




      $

      0.33



         Loss from Discontinued Operations, Net of Tax

      $

      (0.03)




      $

      -



         Net Income

      $

      0.07




      $

      0.33













      Weighted Average Shares Outstanding










           Basic


      30,089





      29,623



           Diluted


      30,956





      29,912























      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Six Months Ended June 30, 2013 and 2012

      (in thousands, except per-share data)













      2013



      2012





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      136,209




      $

      147,701



           Commissions, Allowances and Rebates


      228





      1,316



      Net Sales


      135,981





      146,385













           Other


      1,707





      976













      Net Revenues


      137,688





      147,361













           Cost of Goods Sold


      93,688


      68.8%



      96,488


      65.3%











      Gross Profit


      44,000


      32.3%



      50,873


      34.4%











      Operating Expenses










           Selling, General and Administrative Expenses


      21,726


      16.0%



      21,919


      14.8%

           Research and Development Expenses


      4,959


      3.6%



      4,950


      3.4%

      Total Operating Expenses


      26,685


      19.6%



      26,869


      18.2%











           Gain on Sale of Asset


      4,680


      3.4%



      -


      -











      Operating Profit


      21,995


      16.1%



      24,004


      16.3%











      Other Expenses:










           Interest Expense, net


      983





      1,329



           Other Expenses, net


      6





      24



           Equity in Losses of Partially-Owned Affiliates


      1,149





      591













      Income Before Income Taxes


      19,857


      14.6%



      22,060


      14.9%











           Provision for Income Taxes


      5,296





      5,094













      Income from Continuing Operations

      $

      14,561


      10.7%


      $

      16,966


      11.5%











      Loss from Discontinued Operations, Net of Tax


      (1,119)





      -













      Net Income

      $

      13,442


      9.9%


      $

      16,966


      11.5%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.48




      $

      0.57



         Loss from Discontinued Operations, Net of Tax

      $

      (0.03)




      $

      -



         Net Income

      $

      0.45




      $

      0.57













      Diluted Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.47




      $

      0.57



         Loss from Discontinued Operations, Net of Tax

      $

      (0.03)




      $

      -



         Net Income

      $

      0.44




      $

      0.57













      Weighted Average Shares Outstanding










           Basic


      30,029





      29,612



           Diluted


      30,870





      29,892























      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of June 30, 2013 and December 31, 2012

      (in thousands)















      June 30,



      December 31,

      Assets


      2013



      2012







      Cash and Cash Equivalents

      $

      19,547


      $

      23,551

      Trade Receivables, net


      42,560



      43,094

      Inventories, net


      96,765



      71,221

      Prepaid Expenses and Other Current Assets


      12,085



      6,104

        Total Current Assets


      170,957



      143,970







      Property, Plant and Equipment, net


      161,927



      151,815

      Goodwill


      37,051



      37,312

      Intangible Assets, net


      3,930



      4,091

      Investments in and Advances to Partially-Owned Affiliates


      14,594



      15,094

      Deferred Income Taxes


      38,215



      39,262

      Other Non-Current Assets


      8,869



      2,924







        Total Assets

      $

      435,543


      $

      394,468







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      33,305


      $

      27,612

      Deferred Revenue


      11,366



      11,570

      Accrued Expenses and Other Current Liabilities


      38,608



      43,844

        Total Current Liabilities


      83,279



      83,026







      Long-Term Debt


      87,000



      64,000

      Deferred Income Taxes


      19,615



      18,577

      Accrued Pension Benefits


      53,561



      55,373

      Other Non-Current Liabilities


      15,205



      10,195







        Total Liabilities

      $

      258,660


      $

      231,171







        Stockholders' Equity

      $

      176,883


      $

      163,297







        Total Liabilities and Stockholders' Equity

      $

      435,543


      $

      394,468



















      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Six Months Ended June 30, 2013 and 2012

      (in thousands)









      Second Quarter 2013



      Second Quarter 2012








      Operating Profit

      $

      5,864



      $

      13,894








      Depreciation and Amortization


      5,553




      5,324








      EBITDA

      $

      11,417



      $

      19,218


























































      Six Months 2013



      Six Months 2012








      Operating Profit

      $

      21,995



      $

      24,004








      Gain on Sale of Asset


      (4,680)




      -








      Adjusted Operating Profit


      17,315




      24,004








      Depreciation and Amortization


      10,886




      10,810








      Adjusted EBITDA

      $

      28,201



      $

      34,814






















      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.